Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058633 | 0.87 | JAK2 (0.43) | — | |
| SCHEMBL3567709 | 0.81 | F11 (0.41) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3563606 | 0.78 | CA12 (0.40) | ALDH1A1CHRM4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20511866 | 0.76 | CA12 (0.40) | HSD17B10ALDH1A1HPGDHRH3F11 | |
| SCHEMBL5371783 | 0.72 | ADRA1D (0.51) | CYP2D6TSHRCHRM4SMN1; SMN2HRH3 | |
| SCHEMBL761722 | 0.71 | PRKCA (0.51) | HSD17B10ALDH1A1HPGDTSHRHIF1A | |
| SCHEMBL3495400 | 0.70 | SLC6A9 (0.55) | — | |
| SCHEMBL3555626 | 0.69 | POLB (0.48) | — | |
| SCHEMBL4064856 | 0.68 | OPRD1 (0.46) | ALDH1A1SMN1; SMN2KMT2AHRH3KDM4E | |
| SCHEMBL3598151 | 0.68 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1942733-B1 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7834031-B2 | Radiolabeled glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| EP-1729772-A4 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1942733-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| WO-2007041025-A2 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1729772-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck and Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | SLC6A5, SLC1A5, SLC1A3 | HSD17B10 1654/4885ALDH1A1 3197/4885CYP2D6 3027/4885 |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | HSD17B10 1654/4885ALDH1A1 1871/4885CYP2D6 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.